Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab
Please always quote using this URN: urn:nbn:de:bvb:20-opus-371526
- Blinatumomab is a first-in-class immunotherapy based on the bispecific T-cell engager (BiTE®) immune-oncology platform, which redirects CD3+ T cells to kill CD19+ target cells. The objective of this analysis was to describe the correlation between B- and T-cell kinetics and response to blinatumomab in patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The clinical efficacy of treatment with blinatumomab in patients with r/r NHL was recently investigated in a phase 1 dose-escalation and expansion trial (NCT00274742) whereinBlinatumomab is a first-in-class immunotherapy based on the bispecific T-cell engager (BiTE®) immune-oncology platform, which redirects CD3+ T cells to kill CD19+ target cells. The objective of this analysis was to describe the correlation between B- and T-cell kinetics and response to blinatumomab in patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The clinical efficacy of treatment with blinatumomab in patients with r/r NHL was recently investigated in a phase 1 dose-escalation and expansion trial (NCT00274742) wherein 76 patients received blinatumomab by continuous intravenous infusion at various doses (0.5–90 μg/m2/day). B-Cell depletion and expansion of CD3+, CD4+, and CD8+ T cells was analyzed in patients stratified per clinical response (complete response [CR], n = 16; partial response [PR], stable disease [SD], or progressive disease [PD], n = 54) for at least 4 weeks (additional 4 weeks after clinical benefit) from the date of administration of blinatumomab until dose-limiting toxicity or PD. B-cell depletion kinetics were faster in patients who had a CR than in patients who did not have a complete response (PR, SD, or PD). T-cell expansion (T-cell counts exceeding the baseline level on day 22) was more pronounced in patients with CR than in patients without CR. T-cell expansion in patients with CR correlated with increased T-cell counts of both CD4+ and CD8+ T cells compared with patients without CR. Patients with r/r NHL who achieved a CR had faster B-cell depletion and increased expansion of CD3+, CD4+, and CD8+ T cells than patients who did not achieve a CR.…
Author: | Virginie Nägele, Gerhard Zugmaier, Maria-Elisabeth Goebeler, Andreas Viardot, Ralf Bargou, Peter Kufer, Matthias Klinger |
---|---|
URN: | urn:nbn:de:bvb:20-opus-371526 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Comprehensive Cancer Center Mainfranken |
Language: | English |
Parent Title (English): | Experimental Hematology |
Year of Completion: | 2021 |
Volume: | 100 |
Pagenumber: | 32-36 |
Source: | Experimental Hematology (2021) 100:32-36. https://doi.org/10.1016/j.exphem.2021.06.005 |
DOI: | https://doi.org/https://doi.org/10.1016/j.exphem.2021.06.005 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Release Date: | 2024/09/19 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |